Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Short-term Investments (2019 - 2025)

Orthopediatrics (KIDS) has disclosed Short-term Investments for 7 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments rose 3.0% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 3.0% increase, with the full-year FY2024 number at $25.0 million, down 49.21% from a year prior.
  • Short-term Investments was $2.1 million for Q3 2025 at Orthopediatrics, roughly flat from $2.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $109.3 million in Q4 2022 to a low of $1.4 million in Q1 2022.
  • A 5-year average of $38.5 million and a median of $26.1 million in 2024 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: tumbled 97.52% in 2021, then surged 7907.25% in 2022.
  • Orthopediatrics' Short-term Investments stood at $1.4 million in 2021, then soared by 7907.25% to $109.3 million in 2022, then crashed by 54.94% to $49.3 million in 2023, then tumbled by 49.21% to $25.0 million in 2024, then tumbled by 91.77% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for KIDS's Short-term Investments are $2.1 million (Q3 2025), $2.1 million (Q2 2025), and $2.0 million (Q1 2025).